Evotec OAI Expands ADMET Platform, EVOprofile

Hamburg, Germany | Oxfordshire, UK - Evotec OAI AG (Deutsche Börse: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and biotechnology industries, today announced the successful expansion of their in vitro and in silico ADMET platform, EVOprofile(TM). This platform assists Evotec OAI's customers in profiling their drug candidates with respect to their pharmacokinetic, physiochemical, safety and toxicological properties in order to reduce the risk for potential failure in later clinical development.
Evotec OAI has fully integrated the EVOprofile(TM) technologies into its innovative medicinal chemistry platform utilising a wide variety of screening formats. Several Evotec OAI customers already benefit from a guaranteed rapid turnaround, the real-time availability of validated data and attractive business packages. Evotec OAI plans to further expand its portfolio by adding additional in vitro and in silico assays throughout 2004.
Mark Ashton, PhD, President Drug Discovery Services at Evotec OAI said: "Evotec OAI has a long-standing track record in providing critical ADMET data to clients either on a stand-alone basis or integrated within a medicinal chemistry programme. For example our GLP and non-GLP hERG profiling is used by more than 60 customers worldwide. With the expansion of our EVOprofile(TM) platform we are now uniquely positioned to provide integrated solutions to our partners for faster access to and prioritisation of validated hits and leads and to save months and even years in downstream development time and costs."
Renato Skerlj, Vice President Chemistry at AnorMed Inc. commented: "Determining physiochemical properties such as solubility and permeability within a given structural class provides valuable information for compound prioritisation prior to further PK studies. We have found the early ADMET solutions at Evotec OAI very useful in assisting us in making effective decisions around our compound series of interest."
About Evotec OAI AG
Evotec OAI has established itself as the partner of choice for drug discovery and development solutions for pharmaceutical and biotechnology companies worldwide, maintaining its leadership role through innovation and unmatched customer service.
The Company's business strategy is clearly focussed on drug discovery. It has established the most comprehensive technology platform and skills that integrate its world-class biology and chemistry capabilities. Evotec OAI leverages this discovery engine in providing assay development and screening through to compound optimisation and drug manufacturing services to a broad and well-established network of customers. In addition, the Company engages in selected discovery programmes itself to develop drug candidates for early out-licensing. Evotec OAI's instrument and technology business is now successfully handled by its affiliate, Evotec Technologies.
With over 600 people in Hamburg, Germany and Oxfordshire, UK, Evotec OAI is dedicated to returning value to its shareholders and employees through a sustainable business strategy that balances short-term and long-term revenue opportunities.

Contact: Anne Hennecke, Investor Relations & Corporate Communications, Evotec OAI AG, phone: +49-40-56081-286, anne.hennecke@evotecoai.com
Contact: Anne Hennecke, Investor Relations & Corporate Communications, Evotec OAI AG, phone: +49-40-56081-286, anne.hennecke@evotecoai.com